NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,847,798 | +56.2% | 356,285 | +106.6% | 0.08% | +53.8% |
| Q2 2023 | $4,384,391 | -67.1% | 172,478 | -53.2% | 0.05% | -71.3% |
| Q1 2023 | $13,325,107 | +5.7% | 368,606 | +15.8% | 0.18% | +7.1% |
| Q4 2022 | $12,607,214 | -20.1% | 318,364 | -6.0% | 0.17% | -23.5% |
| Q3 2022 | $15,788,000 | -27.0% | 338,790 | -31.4% | 0.22% | -33.6% |
| Q2 2022 | $21,641,000 | +8.1% | 493,741 | +78.3% | 0.33% | +2.5% |
| Q1 2022 | $20,027,000 | +149.5% | 276,881 | +179.7% | 0.32% | +182.6% |
| Q4 2021 | $8,026,000 | -57.9% | 99,005 | -39.6% | 0.12% | -63.0% |
| Q3 2021 | $19,068,000 | +3010.6% | 163,842 | +4329.4% | 0.31% | +2727.3% |
| Q2 2021 | $613,000 | -92.5% | 3,699 | -94.7% | 0.01% | -96.7% |
| Q4 2019 | $8,138,000 | – | 69,233 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |